The National Cancer Institute (NCI) of the National Institutes of Health is pleased to announce the signing of two new memoranda of understanding (MOUs) for international cancer research and care, as well as new efforts in the emerging scientific area of proteogenomics for precision oncology. MOUs...
COVID-19 is an emerging, rapidly evolving siituation.
What people with cancer should know: https://www.cancer.gov/coronavirus
Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers
Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus
News and Announcements
All | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010
Displaying 41 - 60 of 241March 1, 2021
February 22, 2021
Glioblastoma is among the most aggressive and devastating of cancers. While rare compared with other cancers, it’s the most common type of brain cancer. Even with intensive therapy, relatively few patients survive longer than two years after diagnosis, and fewer than 10% of patients survive beyond...
January 26, 2021
Prostate cancer screening is typically done by evaluation of levels of prostate-specific antigens (PSA). Unfortunately, its effectiveness in stratifying low risk patients from those with aggressive (AG) prostate cancer is poor. Localized in the Golgi, α (1,6) fucosyltranferase (FUT8), a...
January 7, 2021
Proteogenomic analysis may offer new insight into matching cancer patients with an effective therapy for their particular cancer. A new study identifies three molecular subtypes in head and neck squamous cell carcinoma (HNSCC) that could be used to better determine appropriate treatment.
December 15, 2020
Activating point mutations in ErbB/Her2 receptor tyrosine kinases have an infamous role in promoting oncogenesis across several different cancers, including breast and lung. Heterodimer activation of the ErbB2/ErbB3 oncogenic unit induces cancer cell proliferation via PI3K/AKT signaling pathways.
December 8, 2020
In case you missed it, this final article (part 2 of 2) in the Investigator Spotlight Series, developed and written by Dr. Dawn Hayward, Office Clinical Cancer Proteomic Research (OCCPR) NCI Communications Fellow, highlights our up and coming Clinical Proteomic Tumor Analysis Consortium (CPTAC)...
December 1, 2020
A comprehensive “proteogenomic” analysis of the proteins, genes, and RNA transcription involved in pediatric brain tumors has yielded a more complete understanding of these tumors, which are the leading cause of cancer-related deaths in children. The results could help physicians more accurately...
November 18, 2020
Researchers at Baylor College of Medicine, the Broad Institute of MIT and Harvard and other institutions have applied powerful proteogenomics approaches to better understand the biological complexity of breast cancer. With this approach, the researchers were able to propose more precise diagnostics...
November 3, 2020
In a recent publication in the journal Clinical Chemistry, CPTAC investigators from Fred Hutchinson Cancer Research Center described a robust technique for evaluating biomarker expression of key receptors in patients with breast cancer bone metastasis using non-decalcified bone biopsies in immuno...
October 20, 2020
Protein glycosylation, the enzymatic process that attaches glycans or sugar molecules to proteins, plays a crucial role in cancer development processes, such as cell-cell adhesion, cell growth, ligand-receptor binding, and tumor metastasis. Aside from phosphorylation, other protein modifications have...
October 13, 2020
Almost 18 months ago, CPTAC researchers from the Integrative Omics Group at Pacific Northwest National Laboratory (PNNL), developed a stream-lined technique to increase the sensitivity of peptide phospho-group identification during mass spectral...
October 4, 2020
In case you missed it, this third article (part 1 of 2) in the Investigator Spotlight Series, developed and written by Dr. Dawn Hayward, Office Clinical Cancer Proteomic Research (OCCPR) NCI Communications Fellow, highlights our up and coming Clinical Proteomic Tumor Analysis Consortium (CPTAC)...
September 14, 2020
Announcing our newest data release for the Clinical Proteomic Tumor Analysis Consortium (CPTAC) Lung Squamous Cell Carcinoma (LSCC) Discovery study! Because LSCC accounts for about 30% of all lung cancers and has a ~20% 5-year survival rate, it’s imperative that cancer researchers learn more about...
September 8, 2020
In a recent issue of Nature Communications, Clinical Proteomics Tumor Analysis Consortium (CPTAC) researchers from Bing Zhang’s lab at Baylor College of Medicine describe a new bioinformatics software tool developed to evaluate the quality of variant peptide identifications. Using a deep learning...
September 3, 2020
The Clinical Proteomic Tumor Analysis Consortium (CPTAC) is pleased to announce its Virtual Scientific Symposium 2020, September 22nd, 2020. This year’s symposium will feature talks by leaders in the field of proteogenomics and will focus on CPTAC’s tumor characterization and translational studies...
August 13, 2020
The NCI’s Small Business Innovation Research (SBIR) Development Center has released a program solicitation (PHS 2021-1) which includes a new, Clinical Proteomic Tumor Analysis Consortium (CPTAC)-inspired grant. The announcement calls for the development of high-throughput, single-cell, unbiased...
July 30, 2020
This article is the second in the Investigator Spotlight Series that was the brain child of Dr. Dawn Hayward, a NCI Communications Fellow at OCCPR, highlighting our CPTAC researchers and thier work. In case you missed it the first time, here she features CPTAC scientists Dr. David Fenyö and...
July 24, 2020
Online on July 24th on Cell Systems, Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers shared the results of their first-ever, crowd-sourced NCI-CPTAC DREAM Proteogenomic Challenge. In this community-based, collaborative contest participants developed computational algorithms to...
July 14, 2020
A major goal for NCI’s Cancer Proteomic Tumor Analysis Consortium (CPTAC) is to translate proteomic technologies into clinical use to improve treatment and diagnosis of cancer. Dr. Amanda Paulovich and team from the Fred Hutchinson Cancer Research Center (members of the CPTAC Consortium) have...
July 9, 2020
Two new studies released July 9th, 2020 in Cell unravel the biology of lung adenocarcinoma (LUAD) using a suite of molecular techniques that, combined, provide a more complete picture of the disease than ever before.